Conversations in Lung Cancer Research

Thoracic Oncology Group Of Australasia (TOGA)
  • 0.0 (0)
  • MEDICINE
  • UPDATED BIWEEKLY

Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.

  1. TOGA ASM 2026: Program Review

    APR 16

    TOGA ASM 2026: Program Review

    In this episode of 'Conversations in Lung Cancer Research,' host A/Prof Surein Arulananda (Medical Oncologist, Monash Health) is joined by members of the Local Organising Committee to provide an exclusive preview of the 2026 TOGA Annual Scientific Meeting (ASM). The panel discusses the most anticipated sessions, emerging themes in thoracic oncology, and the evolving landscape of lung cancer care in Australia and New Zealand. (00:00) Welcome and Acknowledgement (00:40) Meet the Panel (01:21) Nursing Priorities (02:09) Precision Survivorship (03:25) Respiratory Viewpoint (05:22) Nodule Management (06:46) Radiation Oncology Sessions (09:22) Must See Immunotherapy (11:42) Small Cell Spotlight (12:45) One Session for Everyone (14:45) Debates and AI (17:30) Closing Thanks Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    18 min
  2. ALK TKI Sequencing in the Australian Landscape

    APR 9

    ALK TKI Sequencing in the Australian Landscape

    In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually. (00:00) Welcome and Acknowledgement (00:43) Meet the Expert Guests (01:40) ALK History and Breakthroughs (03:48) Who Gets ALK Lung Cancer (04:57) Workup and Staging Essentials (05:54) Patterns of Spread and Clots (07:24) Second Generation TKIs Standard (09:03) Long Term Toxicities (11:07) Progression Assessment and LAT (12:50) Lorlatinib After Progression (15:46) Lorlatinib First Line Crown Data (17:11) Choosing and Dosing Lorlatinib (20:55) Managing Lorlatinib Side Effects (22:29) Predicting Response and Follow Up (29:30) Next Generation Inhibitors NAL (32:04) Early Stage and Adjuvant TKIs (36:32) Beyond TKIs Chemo and ADCs (39:30) Patient Support and Closing Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    41 min
  3. Professor Michael Millward: Clinical Insights in Lung Cancer Research

    FEB 26

    Professor Michael Millward: Clinical Insights in Lung Cancer Research

    In this episode of 'Conversations in Lung Cancer Research,' A/Prof Mel Moore talks with Prof Michael Millward, Foundation Professor of Clinical Cancer Research at the University of Western Australia and the oncology Medical Director at Linear Clinical Research in Perth. They discuss Prof Millward's extensive background in clinical and research interests in lung cancer and melanoma, the evolution of clinical trials, and the future of medical oncology, touching on molecular diagnostics, liquid biopsies, and early phase drug development. Millward also shares personal anecdotes and practical advice for young oncologists seeking to integrate clinical research into their careers. (00:00) Introduction and Acknowledgements (00:31) Guest Introduction: Professor Michael Millward (01:49) Early Career and Training (05:23) Specialisation in Oncology (08:15) Advancements in Molecular Oncology (15:03) Building a Phase One Unit (21:37) Mentorship and Future of Clinical Trials (28:23) Future of Lung Cancer Treatment (30:33) Closing Remarks and Final Thoughts   Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    33 min
  4. Dr. Megan Sanders: From Science to TOGA Leadership

    FEB 12

    Dr. Megan Sanders: From Science to TOGA Leadership

    In this episode of Conversations in Lung Cancer Research, host A/Prof Mel Moore interviews Dr. Megan Sanders, the Chief Executive Officer of TOGA. They discuss Megan's journey from working in vaccine formulation to earning a PhD in immunology, working in clinical trials, and eventually leading TOGA. They explore the challenges and achievements of TOGA, the importance of multidisciplinary engagement in lung cancer treatment, and the organisation's strategic plan for strengthening research and membership engagement. The conversation touches on the potential of clinical quality registries to improve patient care and highlights the ongoing effort to address the gaps in funding and equitable care for lung cancer patients. (00:00) Introduction and Acknowledgements (00:36) Meet Dr. Megan Sanders: From Science to Leadership (01:21) Journey from Academia to Clinical Trials (05:27) Challenges and Rewards in Clinical Trials (09:24) TOGA's Achievements and Multidisciplinary Approach (26:39) Future Directions and Strategic Plans (36:55) Conclusion and Final Thoughts   Links:  Dr Megan Sanders https://www.linkedin.com/in/megan-sanders-20130156/ TOGA Strategic Plan: https://thoraciconcology.org.au/news/toga/toga-launches-new-strategic-plan-2025-2028-to-advance-thoracic-cancer-research-in-australasia/ TOGA ASM 2026:https://thoraciconcology.org.au/events/toga-annual-scientific-meeting-2026/ Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    38 min
  5. Lung Cancer Research: 2025 Year in Review

    JAN 29

    Lung Cancer Research: 2025 Year in Review

    In this episode of 'Conversations in Lung Cancer Research,' hosted by Associate Professor Mal Itchens, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Professor Nick Pavlakis from Royal North Shore Hospital and Associate Professor Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the 2025 lung cancer screening program, anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. The episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices. 00:00 Introduction to Lung Cancer Research Podcast 00:37 Panel Introduction and Discussion Overview 01:18 Lung Cancer Screening in Australia 02:30 Impact of Screening on Diagnostic Services 06:45 Screening Program Benefits and Challenges 10:34 Future of Lung Cancer Screening 15:54 Advancements in Diagnostic Technology 20:57 Therapeutic Developments in Lung Cancer 24:34 New Drug Listings and Their Impact 40:04 Immunotherapy and Future Directions 44:13 Conclusion and Final Thoughts     Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    48 min
  6. New and Emerging Practice Standards in ES-SCLC

    12/11/2025

    New and Emerging Practice Standards in ES-SCLC

    In this episode of 'Conversations in Lung Cancer Research,' host Dr. Rebecca Tay and fellow oncologists A/Prof Surein Arulananda and Dr. Dasantha Jayamanne (DJ) delve into the latest advances in small cell lung cancer treatment. They explore new first-line treatments, including checkpoint inhibitors and emerging novel agents like lurbinectedin and tarlatamab, highlighting their mechanisms, survival benefits, and toxicity management. The panel also discusses the evolving role of radiotherapy and future directions involving precision medicine and biomarkers. This comprehensive discussion aims to inform clinicians and healthcare professionals about the promising advancements reshaping the small cell lung cancer treatment landscape. This episode is sponsored by Roche. TOGA's SCLC Masterclass will take place 20 March 2026, at Novotel on Collins, Melbourne An advanced workshop covering evolving standards of care and new therapies in SCLC. Early bird tickets available until 16 Feb 2026 > https://thoraciconcology.org.au/events/masterclass-small-cell-lung-cancer/ RESOURCES AND LINKS: CREST trial https://pmc.ncbi.nlm.nih.gov/articles/PMC3058352/ Caspian Study https://www.sciencedirect.com/science/article/pii/S1525730425001640 CHEST RT https://trog.com.au/trials/trog-20-01-chest-rt/ DeLLphi-303 https://www.annalsofoncology.org/article/S0923-7534(25)04288-7/fulltext IMforte https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8006 Japan study PCI vs MRIhttps://pubmed.ncbi.nlm.nih.gov/28343976/ TIMESTAMPS: (00:00) Introduction and Acknowledgements (00:36) Overview of Small Cell Lung Cancer (02:03) Current First-Line Treatments (06:59) Radiotherapy in Small Cell Lung Cancer (11:36) New Developments in Maintenance and Second-Line Treatments (15:35) Exciting New Therapies and Future Directions (24:01) Radiotherapy and Immune Engaging Therapies (32:53) Conclusion and Future Events KEYWORDS: SCLC, ES-SCLC, Small Cell Lung Cancer, Early Stage Small Cell Lung Cancer Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    39 min
  7. Exploring Lung Cancer Care and Research in New Zealand

    11/27/2025

    Exploring Lung Cancer Care and Research in New Zealand

    In this episode of 'Conversations in Lung Cancer Research' hosted by Dr Alex Davis, features a discussion with Dr. Laird Cameron and Dr. Annie Wong on the current state of lung cancer care and research in New Zealand. The panel explores the challenges and disparities faced by thoracic cancer patients, particularly among the indigenous Māori population. The conversation highlights the differences between patient populations in New Zealand and Australia, the impact of rurality on cancer care, the importance of clinical trials and multinational collaborations, and the future prospects for lung cancer treatments and interventions.   (00:00) Introduction and Acknowledgements (01:01) Exploring Lung Cancer in New Zealand (01:13) Meet the Experts: Dr. Laird Cameron and Dr. Annie Wong (01:48) Challenges in Lung Cancer Diagnosis and Treatment (02:44) Specialisation Stories: Why Lung Cancer? (05:20) Comparing Patient Populations: New Zealand vs. Australia (07:44) Lung Cancer Care Pathways in New Zealand (09:17) Access to Treatments and Therapies (14:57) The Role of Lung Cancer Nurses (18:21) Rural Challenges in Lung Cancer Care (22:06) Radiology and Diagnostic Delays (23:08) CTDNA and Liquid Biopsy in New Zealand (25:03) Strengths and Weaknesses in Lung Cancer Care (29:29) The Impact of Clinical Trials and TOGA (33:00) Future Interventions and Wishlists (39:33) Concluding Thoughts and Farewell Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    40 min
  8. Challenging Ageism: Optimising Lung Cancer Treatment in Older Adults

    10/02/2025

    Challenging Ageism: Optimising Lung Cancer Treatment in Older Adults

    In this episode of Conversations in Lung Cancer Research, hosted by Dr Michael Krasovitsky, a medical oncologist at St. Vincent's Hospital in Sydney, the focus is on lung cancer in older adults. The distinction and application of geriatric oncology are explored through comprehensive discussions with experts: A/Prof Christopher Steer, Prof Shalini Vinod, and Ms Nicole Webb. The conversation delves into the importance of geriatric assessments, the unique challenges faced by older patients undergoing cancer treatment, the impact of ageism, and the necessity of tailored, supportive care. Practical tools and approaches for assessing frailty, treatment decision making, and addressing the stigma surrounding lung cancer and aging are also detailed. The episode underscores the critical need for an open, compassionate, and holistic approach to cancer care in older populations.   (00:00) Introduction and Acknowledgements (00:58) Meet the Experts (02:01) Understanding Geriatric Oncology (03:22) Challenges in Clinical Trials for Older Adults (06:53) Geriatric Assessment Tools (10:47) Frailty and Treatment Decisions (14:21)Quality of Life Considerations (17:51) Systemic Therapy Considerations (24:15) Radiotherapy in Older Adults (29:21) Support Systems and Practical Considerations (34:56) Addressing Ageism in Cancer Care (46:19) Stigma and Lung Cancer (49:28) Conclusion and Final Thoughts Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    51 min
See All (66)

Trailer

About

Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.

Information

  • Creator
    Thoracic Oncology Group Of Australasia (TOGA)
  • Years Active
    2020 - 2026
  • Episodes
    66
  • Rating
    Clean
  • Copyright
    Copyright © 2026 TOGA – Thoracic Oncology Group Australasia. No part of this podcast may be reproduced without our written permission.
  • Show Website
    Conversations in Lung Cancer Research

You Might Also Like